Udgrace (Ursodeoxycholic acid) is an epimer of chenodeoxycholic acid. It is a mammalian bile acid found first in the bear and is apparently either a precursor or a product of chenodeoxycholate. Its administration changes the composition of bile and may dissolve gallstones. It is used for the treatment of cholestatic liver diseases including PBC and PSC.
Ursodeoxycholic Acid 300mg/450mg
MODE OF ACTION:
The mechanism of action of UDCA in liver and cholestatic disorders has not yet been explained totally. However, UDCA alters bile acid composition, resulting in increase in the concentration of UDCA and decrease in the concentration of more hydrophobic & potentially toxic bile acids, cholic and chenodeoxycholic acids. UDCA also has a choleretic effect, resulting in increased bile acid output and bile flow. There is some evidence for immunological effects, including a reduction of abnormal expression of HLA Class I antigens on hepatocytes and a suppression of immunoglobulin and cytokine production.
- Alcoholic Liver Disease
- Acute Hepatitis
- Hepatic Disorders
- Liver Cirrhosis
Adults and the elderly:
10-15mg UDCA per kg per day in two to four divided doses are recommended for PBC (primary biliary cirrhosis) and chronic cholestic liver diseases other than CF (cystic fibrosis).
For CF, the general recommended dose is up to 20 mg/kg/day. This dose has been shown to improve histology in PSC patients.
Data on use in children are very limited. In the few available studies, dosages used have generally been up to 15 – 20 mg/kg/day.
In patients with primary biliary cirrhosis, there may, in rare cases, be an initial deterioration in symptoms, e.g. itching.
This information is for registered medical practitioner only. Anyone other than medical practitioner should consult medical practitioner before using this product.